These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26961797)

  • 41. Molecular pathogenesis of B cell malignancy: the role of BCL-6.
    Dalla-Favera R; Migliazza A; Chang CC; Niu H; Pasqualucci L; Butler M; Shen Q; Cattoretti G
    Curr Top Microbiol Immunol; 1999; 246():257-63; discussion 263-5. PubMed ID: 10396064
    [No Abstract]   [Full Text] [Related]  

  • 42. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
    Mitsiades CS; Mitsiades NS; Bronson RT; Chauhan D; Munshi N; Treon SP; Maxwell CA; Pilarski L; Hideshima T; Hoffman RM; Anderson KC
    Cancer Res; 2003 Oct; 63(20):6689-96. PubMed ID: 14583463
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model.
    Yang C; Xiong F; Dou J; Xue J; Zhan X; Shi F; Li M; Wu S; Luo S; Zhang T; Zhang Y; Ming J; Gu N
    Oncotarget; 2015 Sep; 6(29):27714-24. PubMed ID: 26314844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
    Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N
    Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
    World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The ETS Factor Myeloid Elf-1-Like Factor (MEF)/Elf4 Is Transcriptionally and Functionally Activated by Hypoxia.
    Suico MA; Taura M; Kudo E; Gotoh K; Shuto T; Okada S; Kai H
    Biol Pharm Bull; 2016; 39(4):641-7. PubMed ID: 27040637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.
    Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE
    Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
    Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
    Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma.
    Drain S; Flannely L; Drake MB; Kettle P; Orr N; Bjourson AJ; Catherwood MA; Alexander HD
    Leuk Res; 2011 Nov; 35(11):1457-63. PubMed ID: 21705081
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Loss of one copy of Zfp148 reduces lesional macrophage proliferation and atherosclerosis in mice by activating p53.
    Sayin VI; Khan OM; Pehlivanoglu LE; Staffas A; Ibrahim MX; Asplund A; Agren P; Nilton A; Bergström G; Bergo MO; Borén J; Lindahl P
    Circ Res; 2014 Oct; 115(9):781-9. PubMed ID: 25212213
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Germline Lysine-Specific Demethylase 1 (
    Wei X; Calvo-Vidal MN; Chen S; Wu G; Revuelta MV; Sun J; Zhang J; Walsh MF; Nichols KE; Joseph V; Snyder C; Vachon CM; McKay JD; Wang SP; Jayabalan DS; Jacobs LM; Becirovic D; Waller RG; Artomov M; Viale A; Patel J; Phillip J; Chen-Kiang S; Curtin K; Salama M; Atanackovic D; Niesvizky R; Landgren O; Slager SL; Godley LA; Churpek J; Garber JE; Anderson KC; Daly MJ; Roeder RG; Dumontet C; Lynch HT; Mullighan CG; Camp NJ; Offit K; Klein RJ; Yu H; Cerchietti L; Lipkin SM
    Cancer Res; 2018 May; 78(10):2747-2759. PubMed ID: 29559475
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape.
    Liu F; Wang L; Perna F; Nimer SD
    Nat Rev Cancer; 2016 Jun; 16(6):359-72. PubMed ID: 27220480
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.
    Binder M; Rajkumar SV; Ketterling RP; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Hwa YL; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kyle RA; Kumar SK
    Blood Cancer J; 2016 Mar; 6(3):e401. PubMed ID: 26967818
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.
    Pisano M; Cheng Y; Sun F; Dhakal B; D'Souza A; Chhabra S; Knight JM; Rao S; Zhan F; Hari P; Janz S
    Front Immunol; 2021; 12():667054. PubMed ID: 34149703
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modeling the process of human tumorigenesis.
    Balani S; Nguyen LV; Eaves CJ
    Nat Commun; 2017 May; 8():15422. PubMed ID: 28541307
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Roles and regulations of the ETS transcription factor ELF4/MEF.
    Suico MA; Shuto T; Kai H
    J Mol Cell Biol; 2017 Jun; 9(3):168-177. PubMed ID: 27932483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The myeloma stem cell concept, revisited: from phenomenology to operational terms.
    Johnsen HE; Bøgsted M; Schmitz A; Bødker JS; El-Galaly TC; Johansen P; Valent P; Zojer N; Van Valckenborgh E; Vanderkerken K; van Duin M; Sonneveld P; Perez-Andres M; Orfao A; Dybkær K
    Haematologica; 2016 Dec; 101(12):1451-1459. PubMed ID: 27903712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms.
    Asai T; Hatlen MA; Lossos C; Ndiaye-Lobry D; Deblasio A; Murata K; Fleisher M; Cortizas EM; Verdun RE; Petrini J; Nimer SD
    Sci Rep; 2016 Mar; 6():22760. PubMed ID: 26961797
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Rad50S allele promotes ATM-dependent DNA damage responses and suppresses ATM deficiency: implications for the Mre11 complex as a DNA damage sensor.
    Morales M; Theunissen JW; Kim CF; Kitagawa R; Kastan MB; Petrini JH
    Genes Dev; 2005 Dec; 19(24):3043-54. PubMed ID: 16357220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.
    Croonquist PA; Van Ness B
    Oncogene; 2005 Sep; 24(41):6269-80. PubMed ID: 16007202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.